Literature DB >> 15944257

CD27/CFSE-based ex vivo selection of highly suppressive alloantigen-specific human regulatory T cells.

Hans J P M Koenen1, Esther Fasse, Irma Joosten.   

Abstract

Naturally occurring CD4(+)CD25(+) regulatory T cells (Treg) are crucial in immunoregulation and have great therapeutic potential for immunotherapy in the prevention of transplant rejection, allergy, and autoimmune diseases. The efficacy of Treg-based immunotherapy critically depends on the Ag specificity of the regulatory T cells. Moreover, the use of Ag-specific Treg as opposed to polyclonal expanded Treg will reduce the total number of Treg necessary for therapy. Hence, it is crucial to develop ex vivo selection procedures that allow selection and expansion of highly potent, Ag-specific Treg. In this study we describe an ex vivo CFSE cell sorter-based isolation method for human alloantigen-specific Treg. To this end, freshly isolated CD4(+)CD25(+) Treg were labeled with CFSE and stimulated with (target) alloantigen and IL-2 plus IL-15 in short-term cultures. The alloantigen-reactive dividing Treg were characterized by low CFSE content and could be subdivided by virtue of CD27 expression. CD27/CFSE cell sorter-based selection of CD27(+) and CD27(-) cells resulted in two highly suppressive Ag-specific Treg subsets. Each subset suppressed naive and Ag-experienced memory T cells, and importantly, CD27(+) Treg also suppressed ongoing T cell responses. Summarizing, the described procedure enables induction, expansion, and especially selection of highly suppressive, Ag-specific Treg subsets, which are crucial in Ag-specific, Treg-based immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944257     DOI: 10.4049/jimmunol.174.12.7573

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly.

Authors:  Anandharaman Veerapathran; Joseph Pidala; Francisca Beato; Xue-Zhong Yu; Claudio Anasetti
Journal:  Blood       Date:  2011-09-23       Impact factor: 22.113

2.  Perspectives on Regulatory T Cell Therapies.

Authors:  Michael Probst-Kepper; Andrea Kröger; Henk S P Garritsen; Jan Buer
Journal:  Transfus Med Hemother       Date:  2009-09-10       Impact factor: 3.747

3.  T regulatory cell suppression of colitis: the role of TGF-beta.

Authors:  R Duchmann; M Zeitz
Journal:  Gut       Date:  2006-05       Impact factor: 23.059

4.  Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells.

Authors:  M E Christine Lutsiak; Yutaka Tagaya; Anthony J Adams; Jeffrey Schlom; Helen Sabzevari
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

5.  Expanded nonhuman primate tregs exhibit a unique gene expression signature and potently downregulate alloimmune responses.

Authors:  A Anderson; C L Martens; R Hendrix; L L Stempora; W P Miller; K Hamby; M Russell; E Strobert; B R Blazar; T C Pearson; C P Larsen; L S Kean
Journal:  Am J Transplant       Date:  2008-09-17       Impact factor: 8.086

6.  Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells.

Authors:  K P Piper; M Karanth; A McLarnon; E Kalk; N Khan; J Murray; G Pratt; P A H Moss
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

Review 7.  Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse?

Authors:  Joseph Pidala; Claudio Anasetti
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

8.  Ethylenecarbodiimide-coupled allogeneic antigen presenting cells induce human CD4+ regulatory T cells.

Authors:  Michael H Albert; Xue-Zhong Yu; Thomas Magg
Journal:  Clin Immunol       Date:  2008-09-25       Impact factor: 3.969

9.  In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells.

Authors:  Satish N Nadig; Joanna Wieckiewicz; Douglas C Wu; Gregor Warnecke; Wei Zhang; Shiqiao Luo; Alexandru Schiopu; David P Taggart; Kathryn J Wood
Journal:  Nat Med       Date:  2010-05-16       Impact factor: 53.440

10.  Targeting PKC in human T cells using sotrastaurin (AEB071) preserves regulatory T cells and prevents IL-17 production.

Authors:  Xuehui He; Hans J P M Koenen; Ruben L Smeets; Romy Keijsers; Esther van Rijssen; Andreas Koerber; Peter C van de Kerkhof; Annemieke M H Boots; Irma Joosten
Journal:  J Invest Dermatol       Date:  2013-11-05       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.